AHRP Position Statement on Mental Health Screening – FDA Hearing Re: Drug Advertising Wed, 02 Nov 2005 FDA is holding public hearings (Nov 1, 2) Re:Â Direct-to-Consumer Promotion of Medical Products at: National Transportation Safety Board Boardroom and Conference Center 429 L’Enfant Plaza, SW., Washington, DC 2 Time: 9:00 –5:00….
Epidemiologist Says Most Published Research Findings Are False – Psychiatrist Addresses Credibility Crisis Sat, 8 Oct 2005 An article published in PLoS Medical (an Open Access Peer Reviewed Medical Journal) by an epidemiologist who holds academic positions on both sides of the Atlantic–at the University of Ioannina (Greece) and Tufts…
Treating children as young as 4 for bipolar – WSJ Thu, 26 May 2005 A report in The Wall Street Journal should raise serious concerns about the legitimacy of psychiatric diagnosing and drug prescribing for children. The Journal reports that close to 20,000 US children are being diagnosed with bi-polar…
To view AHRP news and infomails from 2006, please visit our new site. Infomails Subscribe to AHRP’s infomails At FDA, Graham is still the whistle-blower Loss of Trust: Big Drug Makers See Sales Decline With Their Image War hero’s death in clinical trial follows years of FDA neglect European perspective:…
"The drugs most commonly used to soothe agitation and aggression in people with Alzheimer’s disease are no more effective than placebos for most patients, and put them at risk of serious side effects, including confusion, sleepiness and Parkinson’s disease-like symptoms, researchers are reporting
today."
Two actions by the FDA last week demonstrate where the agency’s priority lies—and that priority is NOT to protect public safety, NOT to protect children’s safety. FDA’s priority—as demonstrated by its actions—is approval of new drugs or approval for expanded even dubious uses of patented drugs.
“a study published yesterday overturns conventional wisdom about antipsychotic drugs, which cost the United States $10 billion a year.”
No legitimate physician would use the physician’s professional license to help repressive government regimes intimidate dissidents.
Industry’s blockbuster sellers–the atypical antipsychotics performed WORSE than their cheaper, non-patented precursors.
"Even though clinical research is a noble and worthy activity, it’s very easy to lose your moral compass if your primary goal is the dollar amount of grant funding that you generate."
Steven Potkin, who, LAT reports, is a brother-in-law of Jane Pauley who wrapped up her career as TV news anchor to become a paid drug pusher.
8, 362 consumers of Lilly’s top-selling drug that produces diabetes–among other life-threatening effects–can expect between $5,000 to "well over $100,000 a person" depending upon the harm suffered.
